Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11181809 | 0.89 | TP53 (0.58) | BCHERAB9ASMN1; SMN2ATMGAA | |
| SCHEMBL18666169 | 0.84 | MTNR1A (0.61) | SMN1; SMN2ATMGAAMAPTALDH1A1 | |
| SCHEMBL13989319 | 0.84 | GAA (0.73) | RAB9ASMN1; SMN2ATMGAAMAPT | |
| SCHEMBL8277405 | 0.84 | BCHE (0.68) | BCHEMDM2RAB9ASMN1; SMN2MAPT | |
| SCHEMBL13824324 | 0.82 | BCHE (0.59) | BCHEMDM2RAB9ASMN1; SMN2MAPT | |
| SCHEMBL10913949 | 0.81 | HPGD (0.70) | BCHESMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL9912422 | 0.81 | BCHE (0.63) | BCHEMDM2RAB9ASMN1; SMN2GAA | |
| SCHEMBL14817537 | 0.80 | BCHE (0.58) | BCHEMDM2RAB9ASMN1; SMN2HDAC3 | |
| SCHEMBL11928065 | 0.80 | HPGD (0.78) | BCHERAB9ASMN1; SMN2MAPTHDAC3 | |
| SCHEMBL10254172 | 0.79 | BCHE (0.72) | BCHEMDM2RAB9ASMN1; SMN2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101611005-A | Be used as the acetophenones of the replacement of PDE4 inhibitor | LEO PHARMA AS (DK) | 2009-12-23 | — | — | CN | claimed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | claimed |
| CN-1745064-A | Pyridines for the treatment of damaged mammalian neural tissue | PURDUE RESEARCH FOUNDATION (US) | 2006-03-08 | — | — | CN | claimed |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| CN-119841829-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2025-04-18 | — | — | CN | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20220169616-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| US-11130758-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-09-28 | — | — | US | disclosed |
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | WASHINGTON UNIVERSITY (US) | 2021-09-28 | — | — | US | disclosed |
| US-7244748-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2007075414-A2 | CHEMICALLY DERIVATIZED CD4 AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| CN-1745064-A | Pyridines for the treatment of damaged mammalian neural tissue | PURDUE RESEARCH FOUNDATION (US) | 2006-03-08 | — | — | CN | disclosed |
| WO-2005087228-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087750-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| US-5128475-A | PREPARATION OF AMIDES | SHELL OIL COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | BCHE 730/4885MDM2 2536/4885RAB9A 703/4885 |
| US-11130780-B2 | Inhibitors of growth factor activation enzymes | HDGF, MMP7, HGF | BCHE 1002/4885MDM2 3356/4885RAB9A 3807/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | BCHE 1754/4885MDM2 3352/4885RAB9A 2286/4885 |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | AVPR2, AVPR1A, VHL | BCHE 3383/4885MDM2 615/4885RAB9A 716/4885 |
| US-20220169616-A1 | QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | AVPR2, AVPR1A, VHL | BCHE 3383/4885MDM2 615/4885RAB9A 716/4885 |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | P2RY4, INA, PMP22 | BCHE 2093/4885MDM2 3943/4885RAB9A 3684/4885 |
| US-11130758-B2 | Tetrahydropyrazolopyrimidine compounds | SSB, TLR8, TLR9 | BCHE 4842/4885MDM2 2753/4885RAB9A 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.